A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...
The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback